Therapy News and Research

RSS

Alnylam announces new data from ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it will present new data from its ALN-TTR program at the VIIIth International Symposium on Familial Amyloidotic Polyneuropathy being held in Kumamoto, Japan from November 20-22, 2011.

15 Nov 2011

Stem cell therapy remedies heart failure: Study

Heart failure may be sure cured using stem cell therapy claim researchers. In a breakthrough study 16 heart failure patients given stem cells taken from their own bodies showed dramatic and lasting improvement.

15 Nov 2011

Scientists determine atomic structure of Lassa fever viral protein

Scientists at The Scripps Research Institute have determined the atomic structure of a protein that the Lassa fever virus uses to make copies of itself within infected cells.

15 Nov 2011

Long-term AED therapy may increase risk of atherosclerosis in epilepsy patients

New research reveals that patients with epilepsy who were treated for extended periods with older generation antiepileptic drugs (AEDs) may be at increased risk for developing atherosclerosis, a common disorder known as hardening of the arteries.

15 Nov 2011

Positive long-term data from Abbott's ABSORB drug eluting BVS trial on CAD

Abbott today announced positive long-term data from the two-stage ABSORB trial, which is evaluating the ABSORB drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease.

15 Nov 2011

Stem cell therapy within 2 or 3 weeks does not improve heart function after attack

A research network led by a Mayo Clinic physician found that stem cells obtained from bone marrow delivered two to three weeks after a person has a heart attack did not improve heart function.

15 Nov 2011

POZEN reports positive Phase 1 study results comparing PA32540 to clopidogrel for CVDs

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, presented positive results today from a Phase 1 study comparing a dose-timing strategy of PA32540 and clopidogrel spaced 10 hours apart as compared to synchronous administration of enteric-coated (EC) omeprazole (40 mg), enteric-coated aspirin (81 mg) and clopidogrel.

15 Nov 2011

Stem cell injections within two weeks may not help in post heart attack recovery

University Hospitals Case Medical Center researchers could still be close to giving heart attack patients a second chance-just not as they originally thought.

15 Nov 2011

Encouraging results from KAEL-GemVax GV1001 Phase II trial on NSCLC

KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that results from a Phase II trial (CTN-2006) in Stage III non-small cell lung cancer (NSCLC) patients vaccinated with the telomerase peptide GV1001 after chemoradiotherapy and an 8-year update from a phase I/II trial have been published in the November issue of Clinical Cancer, the journal of the American Association for Cancer Research.

15 Nov 2011

Whole-body-vibration does not effectively boost bone density

Whole-body-vibration, a popular exercise which uses a vibrating platform, is sometimes advertised as being able to boost bone density. However, a one-year-study on healthy postmenopausal women has shown that it has no such effect.

15 Nov 2011

Researchers explore how design of chronic and acute pain trials might be improved

For chronic pain sufferers, a day can feel like a year and a year can feel like an eternity. With very few truly new therapies approved by the U.S. Food and Drug Administration for this condition since 2005, the outlook is far from bright.

15 Nov 2011

Experts discuss treatment as prevention at USAID-, World Bank-sponsored debate

In this post in the Center for Global Development's "Global Health Policy" blog, Amanda Glassman, director of Global Health Policy and a research fellow at the center, reports on last week's USAID- and World Bank-sponsored debate on treatment as prevention, "where debaters were asked to support or oppose the proposition that countries should spend the majority of flat or declining HIV prevention budgets on 'treatment as prevention,' building off the results of the HPTN 052 study which found a relative reduction of 89 percent in the total number of HIV-1 transmissions resulting from the early initiation of antiretroviral therapy.

15 Nov 2011

Kessler Foundation researchers to improve rehabilitation after stroke

Kessler Foundation received a $250,000 stroke research grant from the Wallerstein Foundation for Geriatric Life Improvement. Anna Barrett, MD, director of Stroke Rehabilitation Research at Kessler Foundation, will apply the funds to finding better ways to treat hidden disabilities that often complicate recovery after stroke.

15 Nov 2011

Lentigen, UH Case Medical Center initiate LG631 Phase I trial in glioblastoma

University Hospitals (UH) Case Medical Center, Case Western Reserve University School of Medicine and Lentigen Corporation announced today the initiation of a novel Phase I clinical trial of LG631 gene therapy for the protection of hematopoietic stem cells (HSCs) from the dose limiting toxicity of chemotherapy with Temodar.

15 Nov 2011

Scientists discover promising approaches for treatment of pain

Scientists are discovering promising approaches to treating pain, one of the most common and debilitating neurological complaints, according to research released today at Neuroscience 2011, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news about brain science and health.

15 Nov 2011

Mesoblast reports positive Revascor Phase 2 heart failure trial results

Regenerative medicine company Mesoblast Limited today announced positive Phase 2 heart failure trial results of its allogeneic, or off-the-shelf, adult stem cell product Revascor after all patients had completed a minimum follow-up of 12 months, and a mean follow-up of 22 months.

15 Nov 2011

Provectus presents data from PV-10 Phase 2 study at 2011 International Melanoma Congress

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that data and study design features on PV-10 for metastatic melanoma were presented at the 2011 International Melanoma Congress on November 12, 2011, during the 5th Meeting of Interdisciplinary Melanoma/Skin Cancer Centres meeting, in Tampa, Florida.

14 Nov 2011

Bayer and J&J’s blood thinner drug triumphs at late phase clinical trial

Drug makers Bayer AG and Johnson & Johnson’s new blood clot preventing drug can provide life-saving benefits at very low doses in patients who suffer from acute coronary syndrome finds a new clinical trial.

14 Nov 2011

Yissum Research and other investors complete additional investment round of $3 million in Avraham Pharmaceuticals

Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, today announced that it has participated in a U.S. $3 million financing round of Avraham Pharmaceuticals Ltd. together with Pontifax, Clal Biotechnology Industries (CBI), Technion Research and Development Foundation Ltd. (TRDF), Professor Marta Weinstock-Rosin and others.

14 Nov 2011

Stem cell bandage human clinical trial for torn meniscal cartilage

The company behind a pioneering stem cell bandage, believed to be the world's first adult and autologous (patient's own) stem cell treatment designed to heal torn meniscal cartilage, can now take the technology to human clinical trials thanks to an investment from one of the UK's most successful entrepreneurs.

14 Nov 2011

Therapy News and Research

Alnylam announces new data from ALN-TTR01 Phase I trial on TTR-mediated amyloidosis

Stem cell therapy remedies heart failure: Study

Scientists determine atomic structure of Lassa fever viral protein

Long-term AED therapy may increase risk of atherosclerosis in epilepsy patients

Positive long-term data from Abbott's ABSORB drug eluting BVS trial on CAD

Stem cell therapy within 2 or 3 weeks does not improve heart function after attack

POZEN reports positive Phase 1 study results comparing PA32540 to clopidogrel for CVDs

Stem cell injections within two weeks may not help in post heart attack recovery

Encouraging results from KAEL-GemVax GV1001 Phase II trial on NSCLC

Whole-body-vibration does not effectively boost bone density

Researchers explore how design of chronic and acute pain trials might be improved

Experts discuss treatment as prevention at USAID-, World Bank-sponsored debate

Kessler Foundation researchers to improve rehabilitation after stroke

Lentigen, UH Case Medical Center initiate LG631 Phase I trial in glioblastoma

Scientists discover promising approaches for treatment of pain

Mesoblast reports positive Revascor Phase 2 heart failure trial results

Provectus presents data from PV-10 Phase 2 study at 2011 International Melanoma Congress

Bayer and J&J’s blood thinner drug triumphs at late phase clinical trial

Yissum Research and other investors complete additional investment round of $3 million in Avraham Pharmaceuticals

Stem cell bandage human clinical trial for torn meniscal cartilage

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News